ArticleJournal of neuro-oncology2008
The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
Article in Journal of neuro-oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis.AJNR. American journal of neuroradiology · 2013Pooled it
- Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.European journal of nuclear medicine and molecular imaging · 2009Trial
- [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma.Radiation oncology (London, England) · 2008Trial
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.Journal of neuro-oncology · 2022Article
- A rare brainstem anaplastic astrocytoma.Translational neuroscience · 2022Article
- Article
- Diagnostic and Prognostic Potential ofFrontiers in oncology · 2021Article
- Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors.Molecules (Basel, Switzerland) · 2020Review
- Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).Neuro-oncology · 2019Article
- Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma.Frontiers in oncology · 2019Review
- Evaluation of factors influencingNeuroImage. Clinical · 2018Article
- TSPO PET for glioma imaging using the novel ligandEuropean journal of nuclear medicine and molecular imaging · 2017Article
- In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats.Molecular imaging and biology · 2017Article
- Article
- The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.European journal of nuclear medicine and molecular imaging · 2017Article
- Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.Clinical and translational imaging · 2017Review
- Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma.PloS one · 2017Article
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Neuro-oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore prospectively the positive predictive value of O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET)-PET in selected patients with a magnetic resonance imaging (MRI)-based suspicion of a glioma recurrence or progression. Methods Patients with a supratentorial glioma (initial World Health Organization (WHO) grade II, III or IV) were considered eligible if they had both an MRI-(new/progressive contrast-enhancing lesion) and FET-PET-based diagnosis of a recurrence/progression after various forms and combinations of irradiation and chemotherapy. Criterion for tumour recurrence/progression in FET-PET was a standardized uptake value (SUVmax)/Background (BG) ratio of >2.0 in the late uptake phase. All patients underwent multimodal (MRI, FET-PET) imaging-guided stereotactic biopsy. The positive predictive value was defined as the proportion of MRI and FET-PET findings indicating glioma recurrence/progression that also tested positive for tumour recurrence/progression after stereotactic biopsy.
resultsThirty-one patients with initially WHO grade II (17), WHO grade III (6), and grade IV glioma (8) were included. In 26 patients FET-PET results indicating tumour recurrence/progression were concordant with the biopsy results. In five patients histopathologic evaluation failed to reveal a "vital" tumour. FET-PET findings were also discordant with the radiographic and clinical follow-up in these five patients. The positive predictive value of FET-PET was 84%.
conclusionThe positive predictive value of FET-PET using the standard ratio method is high, but not high enough to replace stereotactic biopsy in this highly selected study cohort. Whether the calculation of FET uptake in the early phase and/or the evaluation of uptake kinetics will improve the positive predictive value of FET-PET deserves prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.